Mucosal administration of completely non-replicative vaccinia virus recombinant Dairen I strain elicits effective mucosal and systemic immunity

Scandinavian Journal of Immunology

Volumn 68, Issue 5, 2008, Pages 476-483

  Yoshino, N ^a,b   Kanekiyo, M ^b   Hagiwara, Y ^c   Okamura, T ^b   Someya, K ^b   Matsuo, K ^b   Ami, Y ^b   Sato, S ^a   Yamamoto, N ^b   Honda, M ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c KITASATO INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS GAG POL VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCING CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BRAIN TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENCEPHALITIS; FOOD DEPRIVATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INTESTINE MUCOSA; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PLASMA; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH2 CELL; VACCINIA VIRUS; VIRUS STRAIN;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIFIC PATHOGEN-FREE ORGANISMS; STATISTICS, NONPARAMETRIC; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 53549099384     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02168.x     Document Type: Article

References (33)

1. Belyakov IM, Wyatt LS, Ahlers JD et al. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol 1998 72 : 8264 72.
2. Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001 292 : 69 74.
3. Casimiro DR, Chen RL, Fu TM et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003 77 : 6305 13.
4. + T-cell responses in mucosal tissues of macaques. J Virol 2002 76 : 11659 76.
5. Cebere I, Dorrell L, McShane H et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006 24 : 417 25.
6. Goonetilleke N, Moore S, Dally L et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006 80 : 4717 28.
7. Jaoko W, Nakwagala FN, Anzala O et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008 26 : 2788 95.
8. Kitamura T, Kitamura Y. Interference with the growth of vaccinia virus by an attenuated mutant virus. Jpn J Med Sci Biol 1963 16 : 343 57.
9. Kitamura T, Kitamura Y, Tagaya I. Immunogenicity of an attenuated strain of vaccinia virus on rabbits and monkeys. Nature 1967 215 : 1187 8.
10. Tagaya I, Kitamura T, Sano Y. A new mutant of dermovaccinia virus. Nature 1961 192 : 381 2.
11. Ishii K, Ueda Y, Matsuo K et al. Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector. Virology 2002 302 : 433 44.
12. Someya K, Xin KQ, Matsuo K, Okuda K, Yamamoto N, Honda M. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J Virol 2004 78 : 9842 53.
13. Ami Y, Izumi Y, Matsuo K et al. Prime-boost vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a non-replicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 2005 79 : 12871 9.
14. Someya K, Ami Y, Nakasone T et al. Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol. J Immunol 2006 176 : 1784 95.
15. Kiyono H, Czerkinsky C. Consideration of mucosally induced tolerance in vaccine development. In : Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccine. San Diego : Academic Press, 1996 : 89 101.
16. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 1993 61 : 4272 9.
17. Moldoveanu Z, Fujihashi K. Collection and processing of external secretions and tissues of mouse origin. In : Mestecky J, Lamm ME, McGhee JR, Bienenstock J, Mayer L, Strober W, eds. Mucosal Immunology, 3rd Edn. San Diego : Academic Press, 2005 : 1841 52.
18. Unger RE, Marthas ML, Lackner AA et al. Detection of simian immunodeficiency virus DNA in macrophages from infected rhesus macaques. J Med Primatol 1992 21 : 74 81.
19. Kempe CH. Studies smallpox and complications of smallpox vaccination. Pediatrics 1960 26 : 176 89.
20. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II adverse events. Clin Infect Dis 2003 37 : 251 71.
21. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975 55 : 342 7.
22. Angulo JJ, de Campos EP, de Gomes LF. Postvaccinal meningoencephalitis; Isolation of the virus from the brain. J Am Med Assoc 1964 187 : 151 3.
23. Gurvich EB, Movsesyants AA, Stepenenkova LP. Isolation of vaccinia virus from children with postvaccinal encephalitis at late intervals after vaccination. Acta Virol 1975 19 : 92.
24. Quiding M, Nordström I, Kilander A et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest 1991 88 : 143 8.
25. Kozlowski PA, Cu-Uvin S, Neutra MR et al. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997 65 : 1387 94.
26. Johansson EL, Bergquist C, Edebo A et al. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 2004 22 : 984 90.
27. Johansson EL, Wassén L, Holmgren J et al. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001 69 : 7481 6.
28. Vaerman JP, Langendries A, Giffroy D et al. Lack of SC/pIgR-mediated epithelial transport of a human polymeric IgA devoid of J chain: in vitro and in vivo studies. Immunology 1998 95 : 90 6.
29. Meckelein B, Externest D, Schmidt MA et al. Contribution of serum immunoglobulin transudate to the antibody immune status of murine intestinal secretions: influence of different sampling procedures. Clin Diagn Lab Immunol 2003 10 : 831 4.
30. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007 25 : 5467 84.
31. Chen PJ, Wang JT, Hwang LH et al. Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection. Proc Natl Acad Sci USA 1992 89 : 5971 5.
32. Sjogren M, Hoofnagle JH. Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Gastroenterology 1984 89 : 252 8.
33. Nardelli-Haefliger D, Wirthner D, Schiller JT et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003 95 : 1128 37.